|Over a week ago|
Baird upgrades Vertex Pharmaceuticals, shares attractive ahead of readouts » 08:1602/2302/23/21
As reported previously,…
As reported previously, Baird analyst Brian Skorney upgraded Vertex Pharmaceuticals to Outperform from Neutral with a price target of $252, up from $220. The analyst said the shares were attractive ahead of several readouts and is supported by the CF opportunity. He said any positive news flow for the pipeline has the potential to provide significant upside to the shares.
Vertex Pharmaceuticals upgraded to Outperform from Neutral at Baird » 05:2702/2302/23/21
Baird analyst Brian…
Baird analyst Brian Skorney upgraded Vertex Pharmaceuticals to Outperform from Neutral with a price target of $252, up from $220.
Vertex study of VX-864 completes enrollment, Clinicaltrials.gov shows » 12:5902/2202/22/21
Vertex Pharmaceuticals' study evaluating the efficacy, safety and pharmacokinetics of VX-864 in subjects with a PiZZ genotype has completed enrollment, according to an update on Clinicaltrials.gov. STAT's Adam Feuerstein tweeted:" $VRTX VX-864 clinical trial patient enrollment completed, suggesting no liver tox issues." Shares of Vertex are up 4% to $215.40 in afternoon trading. Reference Link
Freeline appoints Michael Parini as president, COO » 07:2302/1602/16/21
Freeline Therapeutics (FRLN) announced the expansion of its executive leadership team with the appointment of Michael Parini to the newly-created role of President and COO. This appointment complements the recent hires of Stephen Diamond, Jr. as SVP and General Counsel and David Arrington as VP of Investor Relations and Corporate Communications. Michael Parini has been appointed to the role of President and COO, effective March 15, 2021. Parini will be based in the US and will report to CEO. Theresa Heggie, supporting her in executing the Company's global strategy and overseeing critical business and operational functions. These functions include Program Management, Corporate Strategy, Business Development, Legal, Compliance, Investor Relations, Corporate Communications and Information Technology. Parini brings more than 20 years of executive experience in the biopharmaceutical industry, including most recently at Vertex Pharmaceuticals (VRTX), where he served as Executive Vice President and Chief Administrative, Legal and Business Development Officer.
Amicus, BioMarin speculated by Dealreporter as possible Vertex targets » 10:0702/0202/02/21
VRTX, FOLD, BMRN
Following the latest…
Following the latest earnings call from Vertex Pharmaceuticals (VRTX), Dealreporter told its subscribers that questions about what the company is going to buy "do not appear to be going away anytime soon," contacts tell The Fly. The deal-focused publication notes that is has previously highlighted Amicus Therapeutics (FOLD) "as a potential name to keep an eye on" in light of Vertex's previous interest in the gene therapy space, adding that "maybe this is the year that longtime rare disease takeover target" Biomarin Pharmaceutical (BMRN) gets a "serious look" if Vertex "wanted to swing for the fences," contacts tell The Fly.
Vertex Pharmaceuticals price target lowered to $280 from $285 at Credit Suisse » 08:0702/0202/02/21
Credit Suisse analyst…
Credit Suisse analyst Evan Seigerman lowered the firm's price target on Vertex Pharmaceuticals to $280 from $285 and keeps an Outperform rating on the shares following quarterly results. The analyst notes that while Q4 results were "fine" - modest revenue beat, and a slight EPS miss -, investor focus has turned to business development.
Vertex Pharmaceuticals price target lowered to $284 from $302 at BMO Capital » 06:5702/0202/02/21
BMO Capital analyst Do…
BMO Capital analyst Do Kim lowered the firm's price target on Vertex Pharmaceuticals to $284 from $302 but keeps an Outperform rating on the shares. The analyst notes that while the company's FY21 product revenue guidance looks "conservative", he is lowering his EPS view to $11.83 from $12.23. Kim still keeps the $10B or more in peak sales estimate for Vertex and believes that its Trikafta/Kaftrio will continue to grow this year. The analyst adds that the company's pipeline progress, starting with VX-86 phase 2 trial data in the first half of this year, could begin adding "pipeline value".
Vertex Pharmaceuticals price target lowered to $275 from $315 at H.C. Wainwright » 06:3102/0202/02/21
H.C. Wainwright analyst…
H.C. Wainwright analyst Andrew Fein lowered the firm's price target on Vertex Pharmaceuticals to $275 from $315 and keeps a Buy rating on the shares to reflect the company's provided revenue guidance for 2021.
Vertex Pharmaceuticals price target raised to $347 from $307 at Piper Sandler » 05:0602/0202/02/21
Piper Sandler analyst…
Piper Sandler analyst Edward Tenthoff raised the firm's price target on Vertex Pharmaceuticals to $347 from $307 and reiterates an Overweight rating on the shares following the company's Q4 results. The analyst says "strong" cystic fibrosis sales will fund Vertex's "emerging" early stage pipeline.
Fly Intel: After-Hours Movers » 19:1302/0102/01/21
SKY, KMT, HLIT, CRUS, RMBS, WWD, VRTX, ARQT, NXPI, MITK, CURI, RVMD, AXTA
Check out this evening's…